Assay News and Research

RSS

Affymetrix releases complete genotyping data set on its website

Affymetrix, Inc. today announced the release of a complete data set of 5 million variants on its website.

3 Mar 2011

Scientists find reprogramming-associated mutations in hiPSCs

Ordinary human cells reprogrammed as induced pluripotent stem cells may ultimately revolutionize personalized medicine by creating new and diverse therapies unique to individual patients.

3 Mar 2011

Omeros identifies orphan GPCR compounds associated to pancreatic cancer, cognitive disorders

Omeros Corporation today announced that it has identified compounds that interact selectively with two orphan G protein-coupled receptors linked to pancreatic cancer and cognitive disorders.

3 Mar 2011

New microfluidic device may help clinicians to improve cancer therapy

Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.

3 Mar 2011

Wako receives FDA 510(k) clearance for uTASWako i30 with AFP-L3 and DCP assays

Wako Diagnostics, a division of Wako Chemicals USA, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the uTASWako i30 instrument with alpha-fetoprotein L3 (AFP-L3) and des-gamma-carboxy prothrombin (DCP) in vitro diagnostic (IVD) tests in the USA.

2 Mar 2011

Bioanalysis accepted for coverage by EMBASE & Scopus

EMBASE is a premier online resource for biomedical literature, with over 24 million indexed records and more than 7,500 current, mostly peer-reviewed journals, EMBASE quickly and accurately delivers biomedical answers. Scopus is the largest abstract and citation database of research literature and quality web sources covering nearly 18,000 titles from more than 5,000 publishers.

1 Mar 2011

ADC announces RNAscope technology clinical study results for HPV-associated head and neck cancers

Advanced Cell Diagnostics, Inc. today announced the results of its clinical study utilizing RNAscope technology to detect human papillomavirus E6/E7 mRNA in routine clinical specimens of head and neck cancer.

From Advanced Cell Diagnostics 1 Mar 2011

Renishaw launches first RUO multiplex assay system

Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering and surface enhanced resonance Raman scattering, for research and molecular diagnostics applications, today announced the launch of its first research use only multiplex assay system which allows precious research samples to be 'screened' for 10 or more 'targets', from a single sample.

1 Mar 2011

SQI Diagnostics first quarter net loss increases to $2,255,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced its financial and operational results for the first quarter ended December 31, 2010.

28 Feb 2011

Affymetrix introduces new GeneChip miRNA 2.0 Array

Affymetrix, Inc. today launched the GeneChip miRNA 2.0 Array. This enhanced version of its best-in-class microRNA interrogation solution will support the research community's pursuit of personalized medicine by accelerating the identification of biomarkers and gene expression signatures associated with disease.

28 Feb 2011

QIAGEN, Epigenomics enter option agreement to commercialize colorectal cancer blood test

Epigenomics AG, the cancer molecular diagnostics company, and QIAGEN today announced that the companies have entered into an option agreement allowing QIAGEN to develop and, should QIAGEN exercise the option, commercialize a colorectal cancer blood test based on Epigenomics' proprietary biomarker mSEPT9 and certain DNA methylation analysis technologies.

From QIAGEN Manchester Limited 28 Feb 2011

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Protalix BioTherapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease. Taliglucerase alfa is a plant-cell expressed form of glucocerebrosidase (GCD).

25 Feb 2011

Quanterix expands its Single Molecule Array technology to measure proteins precisely

Quanterix Corporation, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced the online publication of a study that builds upon the company's Single Molecule Array technology by combining digital and analog detection in one straightforward measurement.

24 Feb 2011

FDA allows marketing of Ridascreen Norovirus 3rd Generation EIA assay in the US

The U.S. Food and Drug Administration allowed marketing of the first test for the preliminary identification of norovirus.

24 Feb 2011

FDA clears Agendia's breast cancer recurrence assay

Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration clearance for MammaPrint, its widely used breast cancer recurrence assay.

23 Feb 2011

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

A strategy developed by Massachusetts General Hospital (MGH) researchers to shield the ovaries of female mammals from the damaging effects of radiation and chemotherapy has passed an important milestone. A collaborative study with investigators from Oregon Health and Sciences University (OHSU), published online in the journal Fertility and Sterility, reports that brief preexposure of the ovaries to an FDA-approved agent called FTY720 preserved the fertility of female rhesus monkeys exposed to potentially lethal doses of radiation.

23 Feb 2011

Biomoda completes sample collection in pilot study of CyPath diagnostic assay for lung cancer

Cancer diagnostics company Biomoda, Inc. today announced that it has completed patient enrollment and sample collection for the pilot study to determine the clinical sensitivity and specificity of its CyPath® diagnostic assay for the early detection of lung cancer.

23 Feb 2011

NanoString launches fixed-panel assay product for human molecular karyotyping

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the first fixed-panel assay product to be developed on its Copy Number Variation detection platform - the nCounter Human Karyotype Panel.

From NanoString Technologies 22 Feb 2011

MedTrust, Avantra collaborate to develop molecular diagnostic assay for cancer care

MedTrust Online and Avantra Biosciences announced today a novel collaboration to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences' revolutionary QPDx multiplex immunoassay system.

22 Feb 2011

New diagnostic tool to detect patients with active TB disease

Tuberculosis remains one of the most pressing public health priorities for the 21st century, with over one third of the world population infected. Active TB disease is a major issue both for the patients who require specific treatment and at a population level, since these patients are contagious.

21 Feb 2011